To directly compare clinical side effects and biological response modification, IFN-#,,er, IFN-'y, 
Introduction
IFNs are prototype lymphokines with a broad range of antiviral, immunomodulatory, and antiproliferative effects. Three major classes (IFNs alpha, beta, and gamma) have been defined based on differences in amino acid structure. Biologic 1.3-3.3 X 107 units/mg of protein; Biogen, Cambridge, MA) (12) were provided through the Biological Response Modifiers Program, National Institutes of Health (Frederick, MD). IFN-3,,r is a synthetic mutant protein with a substitution of serine for cysteine at amino acid position 17 (13) .
Patient selection. This study was open to patients with histologically confirmed malignancies for which no standard therapy was known to be effective. Eligibility criteria included an Eastern Cooperative Oncology Group performance status of 0 or 1 and adequate hematologic, hepatic, and renal function. Patients could have received no more than two prior cytotoxic chemotherapy regimens and could not have received cytotoxic chemotherapy for at least 3 wk before initiation of IFN (6 wk for mitomycin C or nitrosoureas); radiation therapy, hormones, glucocorticosteroids, for at least 2 wk; or IFN-a or other immunotherapy for at least 4 wk. Patients with clinically significant heart disease, CNS involvement, or prior treatment with IFN43ser or IFN--y were excluded. While on study, patients were not allowed barbiturates, aspirin, corticosteroids, or nonsteroidal antiinflammatory drugs. All patients gave informed consent.
21 patients with a variety of tumor types were entered on study (Table I) . One patient at the higher dose level discontinued therapy within the first 3 wk due to personal reasons and was not evaluated for response.
Study design. Two dose levels were studied (Table II) which was the maximum tolerated dose determined from a previous phase I trial (10) . For all combined treatments, IFN-,y was given first intravenously over 10 min followed by a 10-min injection of IFN-#ser.
Clinical parameters were evaluated before and 24 h after the day 1, 8, and 15 treatment. Each injection was followed by a 1-wk washout period. Clinical parameters, biological response and disease response were assessed again after 4 Monocyte surface antigen expression. Determination of monocyte surface antigen expression was performed as previously described (15 (15) .
The data were analyzed to determine whether the combination of IFN-fser/IFN-i significantly increased HLA-DR expression more than IFN-fser or IFN-'y. A similar fraction of patients had an increase in positive monocytes after all treatments ( Fig. 2, A HLA-DQ expression on monocytes. Significant increases were also seen in the mean percentage of monocytes positive for HLA-DQ after IFN-Aser, IFN--y, and the combination ( Most monocytes (98%, data not shown) however, were positive for this antigen before treatment making it difficult to detect further increases in the number of positive cells. However, there was a significant increase in the MFR (P = 0.01 1, 0.010, and 0.001, respectively) of positive cells (Fig. 3 A) Serum (2 microglobulin. Significant elevations in serum (2 microglobulin were observed 24 h after treatment with all three IFN(s) (P < 0.001) (Fig. 3 B) . All 21 patients receiving IFN-flser and the combination had an increase in their serum (2 which was significantly less than the 1.5-fold increase observed after IFN--y, and the 1.63-fold increase observed after IFN-#,ce/IFN-y (P = 0.05 and 0.001, respectively). The difference between IFN-'y and the combination was not statistically significant (P = 0.08). Elevations in serum 2 microglobulin were maintained after 4 wk of treatment at either dose level (P < 0.001) (Fig. 3 B) . A significant dose response relationship was observed with either IFN-y or IFN-,fser/IFN-y, but not IFN-fser (P = 0.04, 0.01, and 0.38, respectively).
2-5A synthetase activity. IFN-flser increased serum 2-5A
synthetase by a mean of 3.2-fold and in 17 of 20 patients (P < 0.001) (Fig. 4) . Similarly, IFN-fl.,r/IFN-'y increased 2-5A synthetase activity 2.3 times (P = 0.004) and in 15 of 17 patients assessed. IFN-y had no significant effect on 2-5A synthetase activity, increasing it in 7 of 18 patients (P = 0.65). The difference in 2-5A synthetase enhancement between IFN-Aser and the combination was not statistically significant (P = 0.23), although both enhanced 2-5A synthetase more than IFN-y (P < 0.02). No significant dose-response relationship was observed for any of the three treatment arms (P . 0.38) (Fig. 4 A) . The combination IFN-i3,,r/IFN-y maintained 2-SA synthetase activity when administered for 4 wk (P < 0.001) (Fig. 4 B) . Indoleamine 2,3 dioxygenase activity as measured by reduction in serum tryptophan levels. At the lower dose, the combination of IFN-fler/IFN-, produced significant decreases (P ' .01) in serum tryptophan levels at 6 and 24 h (Fig. 5 A) .
Except for IFN-#(3r at 6 h, the individual interferons at dose level A did not produce significant changes in tryptophan levels. At the higher dose, IFN-'y and the combination caused significant (P < 0.04) decreases in tryptophan at all times studied (Fig. 5 B) , decreasing it in 11 of 11 patients, and 10 of 11 patients, respectively.
There was no significant difference between effects of IFN-'y and the combination at 24 h (P = 0.5 1) although both of these treatments produced greater decreases in serum tryptophan than IFN-fler (P < 0.03). A significant dose-response effect was seen for both IFN-y and the combination at 24 h, but not for IFN-B3er (P = 0.004, 0.005, and 0.94, respectively).
Indoleamine 2,3 dioxygenase activity as measured by urinary kynurenine levels. In parallel with the decrease in serum tryptophan levels observed after IFN--y or IFN-fle,/IFN-,y there was a reciprocal increase in urinary excretion of kynurenine at 24 h at both dose levels (P < 0.003) (Fig. 5, C and  D) . IFN-y increased urinary kynurenine levels in 17 of 20 patients, and the combination increased levels in 18 of 20 patients. A significant increase was observed for IFN-(ser at the lower dose levels (six of nine patients) (P = 0.048) but not the higher (five of nine patients) (P = 0.38). As with serum tryptophan levels, the changes in urinary kynurenine induced by IFN-'y and IFN-(3er/IFN-y were not significantly different Effector cell cytotoxicity NK and ADCC activity. IFN-,y decreased NK cell activity by 32% when measured 24 h after treatment (P = 0.026) (Fig. 6 Phase IB Trial Interferon-,ser, Interferon-y, and Interferon-,ls, Interferon-y 1215 Asterisks indicate significant differences compared with baseline with P < 0.05. Error bars = SE.
two dose levels were combined (Fig. 6 B) , ADCC activity was increased 63% (P = 0.042). Serum neopterin levels. Significant increases in serum neopterin levels were observed after all three IFN treatments at both dose levels (Fig. 7) . All three IFN treatments increased serum neopterin in all patients studied. IFN-Iser/IFN--y treatment increased serum neopterin levels by a mean of 3.0-fold, an augmentation that was significantly higher than the 2.2-fold increase induced by IFN-'y, but only marginally significantly higher than the 2.5-fold increase induced by IFN-flser (P = 0.005, and 0.06, respectively). No dose response effect was noted in any of the treatment groups (P 2 0.34). Serum neopterin levels were not obtained after 4 wk of maintenance treatment with IFN-#,Be/IFN--y.
Clinical tolerance Single injections. Subjective side effects were dose related and qualitatively similar to those typically associated with IFN (Table III) . The most common side effects of moderate or greater severity at the lower dose were fatigue and headache. Symptoms of moderate or greater severity were more frequent at the higher dose (Table III) . Incidence of anorexia, nausea, and vomiting was slightly greater after the combination, and incidence of fatigue was slightly higher after IFN-'y. blood pressure were recorded pretreatment and 1, 2, 4, and 6 h after administration of IFN(s). There were no temperatures > 40°C. Mean maximum temperatures were equivalent for both dose levels of IFN-,l.3r (37.9°C). For the higher dose level of IFN-y, mean temperature was higher (38.2°C, range 36.7-38.4) than at the lower (37.5°C, range 37.0-39.7°C). The mean maximum temperature at the higher dose was slightly higher for the combination (38.4°C) than either IFN alone. Acetaminophen (650 mg p.o.) was administered 30 min before treatment and every 4 h for a total dose of 2,600 mg with all treatments at the higher dose level. After 4 wk of maintenance therapy with the combination at the low dose, dose-limiting toxicity was observed in two patients. One patient required dose reduction for grade 3 weight loss (9.4% of baseline) and another for grade 3 fatigue and a performance status decrease of 2 2 levels. After 4 wk of therapy with the combination, the incidence of moderate or severe fatigue, headache, myalgias, and anorexia decreased (Table III) . Four of eight patients at the high dose level had a performance status decrease of 2 2 levels, which was attributed to concomitant disease progression in three of these patients. One patient with severe fatigue, nausea, and vomiting, and grade 4 weight loss (10.3% ofbaseline) required dose modification.
Transaminase elevation (210 IU/liter serum glutamic oxalo acetic acid transferase (SGOT)) was dose limiting in one patient who was receiving 1 X 106 IU of IFN-l8ser with 70 jg IFN-'y after a dose reduction for fatigue.
Laboratory parameters Single injections. Hematologic parameters were measured before and 24 h after single weekly injections. Significant decreases in neutrophils, platelets, hemoglobin, and white blood counts were observed (Table IV) . Although these changes were statistically significant, none were clinically significant. No significant alterations in renal or hepatic function were observed after any of the first injections.
After 4 wk of maintenance therapy with the combination IFN-,ser/IFN-I, there were significant decreases in hemoglobin, hematocrit, neutrophils, total white blood cell count, and significant increases in SGOT and lactate dehydrogenase (LDH) when compared with pretreatment values (Table V) Phase IB Trial Interferon-,fser, Interferon-,y, and Interferon-fse, Interferon--y 1219 IFN alone; furthermore, patients had persisting fevers and progressive fatigue with the daily intramuscular injections ( 11) . In our study, a higher dose level of IFN-flr and IFN--y was tolerable when administered for prolonged periods oftime, a finding that confirms our previous observations (21). The discrepancies between the combination of IFN-a and IFN-flser with IFN-'y may result from the two different type I IFNs (IFNalfa-2a and IFN-fler), by differences in the two IFN-'y formulations which were used, or by differences in route or schedule of administration. Quantification of biological response modification by IFNs has been useful to define differences in IFN types, the influence ofserum levels, duration of response, and modification of effector cell function in vivo (2, 14, 15, 17, 20) . Assessment of host responses was undertaken 24 h after the administration of IFNs, a time identified as yielding modulation in prior studies in vitro and in vivo (2, 14, 15, 17, 20) . While a kinetic analysis would also be of interest, sample volumes from patients are limited; we thus chose to focus study design on the influence of dose. The biological parameters chosen for study were ones that are known to be modulated by IFNs and may be mediators of antitumor activity.
A synergistic enhancement in biological responses was not observed. With the exception of tryptophan metabolism, the differences were not even additive. The combination of IFN43ser/IFN-y was more effective than IFN-fl in enhancing tryptophan metabolism and serum 2 microglobulin, and more effective than IFN-,y in enhancing the expression of 2-5A synthetase and serum neopterin levels. These results are consistent with previous reports that the optimal biological dose was not related to the total dose of IFN (15, 17) , even when the IFN administered consisted of two IFN types.
One biological response, which was enhanced by IFN-B&,r/ IFN-,y in a dose-dependent but not synergistic fashion was the induction of tryptophan metabolism. Indoleamine 2,3-dioxygenase is an enzyme present in the lung and intestinal mucosa that degrades tryptophan and related indoles to kynurenine and other metabolites (23) , and has been found to be induced by viral infections, bacterial lipopolysaccharides, and IFN (23) . We have observed tryptophan degradation induced by IFN in vitro and in vivo (24, 25) . Addition of excess tryptophan to culture media has been able to reverse the antiproliferative effect of IFN--y in several cell lines (26, 27) .
Neopterin, excreted by human monocytes in response to IFN-y, has been used as an assay for monocyte activation (28) .
In this study, the combination of IFN-#,,r/IFN-y-enhanced neopterin levels over IFN-y alone. Furthermore, the increase in neopterin levels produced by the combination, when compared to the increase in neopterin produced by IFN-fl.e bordered on statistical significance (P = 0.057).
We have previously shown that IFN--y and IFN-f enhances HLA-DR and HLA-DQ expression on monocytes in cancer patients (15, 29) ; the current study confirms those observations, extends them to the combination of IFN-#,Br/IFN-y, and determined that IFN-y was no more effective than IFN-4ser, This latter result differed from studies of tumor cell lines in vitro (30, 31) . In contrast, IFN-,B has been shown to have an antagonistic effect on the IFN-y induced expression of Ta antigen in murine macrophages (32) . We found no potentiation of HLA class I or II expression by the combination of IFN-flser/IFN-over either IFN-f3ser or IFN--y.
We observed no enhancement over baseline in NK cell activity with IFN-flBr/IFN-y. These results differ from those observed in immune cells in vitro, in which lymphocyte NK cell activity by IFN-y was potentiated by IFN-a or IFN-,ser (33) . The lack of NK cell enhancement by IFN-flser and the decrease in NK cell activity by IFN-y also differ from the potentiation of NK cell activity we and others have consistently observed with IFN-a and IFN-fl (17, 34, 35) . Other investigators, however, have reported the absence of significant NK cell activity and ADCC activity in patients treated with 4-h infusions of IFN-'y (31), although this has not been confirmed by other groups using a different IFN-y preparation given intramuscularly (36). In this study, ADCC activity was enhanced after 4 wk of the combination treatment. To determine whether this variability in response results from movement of non-MHC-restricted effector cells from circulation to tumor sites, differences in disease stage or type, or active suppression by the IFNs administered, would require additional quantitative studies.
In summary, when compared with either IFN-#l-r or IFN-'y alone, the combination ofIFN-fler/IFN-'y did result in a significantly greater enhancement of serum 12 microglobulin compared with that induced by IFN-flser, a significantly greater increase in urinary kynurenine levels compared to IFN-flser, and a significantly greater increase in neopterin levels and 2-5A synthetase activity compared with IFN-y. Since these changes were not synergistic, we conclude that the combination of IFN-#l.,/IFN-y at this dose and schedule did not potentiate host responses more than either IFN alone. Consistent with these findings, doses of IFN-#1er and IFN--y resulted in no significant added host toxicity.
These results contrast with the synergistic antiproliferative effects that have been observed in vitro and in mouse tumor models (7) (8) (9) (10) . The role of IFN-ler, IFN-y, and IFN-fl.r/ IFN-y in the treatment of cancer has yet to be defined. As 
